CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.85
−4.32%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- 70.36x
- P/S forward
- 47.77x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 6.58x
- Price / sales
- —
- Price / cash flow
- -14.82x
Enterprise value
- Enterprise value
- $678.2M
- EV / sales
- —
- EV / EBITDA
- -8.17x
- EV / EBIT
- -9.42x
- Market cap
- $830.2M
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026